Últimas noticias sobre BioLine Rx (NASDAQ:BLRX) Bolsa

BioLine Rx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLineRx Ltd. - American Depositary Shares

BioLine Rx Ltd

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and lowers the price target from $21 to $9.

News

Price Target

Analyst Ratings

BLRX

HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $9

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.05) by 98 percent. The company reported quarterly sales of $4.94 million which missed the analyst consensus estimate of $5.29 million by 6.57 percent.

Earnings

BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly loss at $0.10 per share on revenue of $4.12 million. 
• Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) is estimated to report earnings for its second quarter. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $227.49 million. 
• Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $68.00 million. 
• Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $1.58 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.16 per share on revenue of $5.95 million. 
<h3>Companies Reporting After The Bell</h3>
• BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $776.51 million. 
• Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $1.67 billion. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) is likely to report quarterly loss at $0.22 per share on revenue of $706.77 million. 
• Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $707.30 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its third quarter. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly loss at $0.02 per share on revenue of $69.82 million. 
• Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $404.09 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $232.90 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $40.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.31 billion. 
• Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is expected to report quarterly earnings at $1.31 per share on revenue of $1.16 billion. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is likely to report quarterly earnings at $1.25 per share on revenue of $812.95 million. 
• Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) is expected to report quarterly earnings at $0.67 per share on revenue of $324.70 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $199.08 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $407.00 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $36.14 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $48.95 million. 
• Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is likely to report quarterly loss at $1.16 per share on revenue of $17.93 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAR

BBWI

BLBD

CENT

CENTA

CRGO

ENTA

FLNC

HSAI

LESL

PFLT

PNNT

SMTC

SUPV

TBBB

UXIN

Earnings Scheduled For November 25, 2024

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is preparing to release its quarterly earnings on Monday, 2024-11-25. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.10.
Anticipation surrounds BioLine Rx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 8.88% increase in the share price on the subsequent day.
Here's a look at BioLine Rx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.29</td>
<td>-0.22</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.01</td>
<td>-0.15</td>
<td>-0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>8.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732284187_0.png" alt="eps graph" />
<h3>BioLine Rx Share Price Analysis</h3>
Shares of BioLine Rx were trading at $0.32325 as of November 21. Over the last 52-week period, shares are down 77.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLRX/earnings">To track all earnings releases for BioLine Rx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioLine Rx

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASMB

BDRX

CATX

CDTX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Health Care

Contracts

General

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and maintains $21 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -&nbsp;
- Data from proof-of-concept&nbsp;study shows that motixafortide was safe and well tolerated -
- Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California -
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX),&nbsp;a commercial&nbsp;stage&nbsp;biopharmaceutical&nbsp;company pursuing&nbsp;life-changing&nbsp;therapies&nbsp;in&nbsp;oncology&nbsp;and rare diseases,&nbsp;today&nbsp;announced&nbsp;that an abstract including the initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for oral presentation&nbsp;at the 66th&nbsp;American Society of Hematology (ASH) Annual Meeting &amp; Exposition taking place&nbsp;December 7-10, 2024 in San Diego, California. The proof-of-concept study, conducted in collaboration with Washington University School of Medicine in St. Louis, is exploring alternative HSC mobilization strategies that could significantly improve the treatment journey of patients with sickle cell disease seeking gene therapy. &nbsp;&nbsp;

BioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024

BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

AKAN

ALLK

CARA

DWTX

IMNM

NIVF

PTIX

TVGN

UNCY

12 Health Care Stocks Moving In Friday's After-Market Session

Shares of Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose sharply in today's pre-market trading after the company confirmed non-binding acquisition <a href="https://www.benzinga.com/quote/ALTM/analyst-ratings">approach by Rio Tinto</a>.
Arcadium Lithium shares jumped 27.8% to $3.94 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 54.5% to $0.1735 in pre-market trading after dipping 17% on Friday.</li>
<li>TDH Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETZ#NASDAQ">PETZ</a>) rose 36.2% to $1.84 in pre-market trading after jumping 13% on Friday.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) gained 16.8% to $1.95 in pre-market trading after declining 5% on Friday.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares gained 13.3% to $14.04 in pre-market trading after jumping around 35% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) shares rose 13.1% to $2.16 in pre-market trading after gaining around 3% on Friday.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares surged 12.6% to $1.25 in pre-market trading after dipping 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares jumped 11% to $4.13 in pre-market trading after gaining 17% on Friday.</li>
<li>The Duckhorn Portfolio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>) shares gained 11% to $6.00 in pre-market trading ahead of quarterly earnings.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) gained 9.5% to $0.5035 in pre-market trading after dipping around 12% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares dipped 39% to $2.81 in pre-market trading after the company announced it received a Nasdaq delisting notification.</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) fell 22.2% to $1.47 in today's pre-market trading. Beneficient shares jumped around 59% on Friday after the company announced its subsidiary, Beneficient Company Holdings, consummated a previously announced transaction pursuant to which approximately $126 million of its preferred equity was redesignated as non-redeemable.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares fell 18.7% to $1.26 in pre-market trading after gaining 4% on Friday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) fell 18.4% to $1.64 in pre-market trading after declining 21% on Friday.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) declined 17.2% to $0.2330 in pre-market trading after dipping around 24% on Friday.</li>
<li>Vicinity Motor Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares declined 17.3% to $0.1448 in pre-market trading after gaining around 23% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) fell 15.8% to $1.75 in pre-market trading after declining 8% on Friday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 15.8% to $12.47 in pre-market trading after jumping 387% on Friday.</li>
<li>Stepan Company  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) shares fell 6.5% to $72.29.</li>
<li>Fortuna Mining Corp. NYSE: FSM) shares declined 5.3% to $4.62 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ALTM

BENF

CETX

CHSN

CTNT

EFSH

FAAS

GSIW

LGMK

MYNA

NAPA

PETZ

TIGR

TRVN

Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Patient&nbsp;survey&nbsp;currently&nbsp;underway in&nbsp;partnership&nbsp;with&nbsp;the&nbsp;HealthTree Foundation; data expected in Q1 2025
TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of <a href="https://www.mobilizationmatters.com/">Mobilization&nbsp;Matters</a>,&nbsp;a&nbsp;digital&nbsp;resource for&nbsp;people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of treatment.

BioLineRx Launches 'Mobilization Matters', A Digital Resource For People With Multiple Myeloma Preparing For Stem Cell Collection; Patient Survey Currently Underway In Partnership With The HealthTree Foundation; Data Expected In Q1 2025

Jones Trading analyst Justin Walsh initiates coverage on BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy rating and announces Price Target of $2.

Initiation

Jones Trading Initiates Coverage On BioLine Rx with Buy Rating, Announces Price Target of $2

WIIM

BioLineRx shares are trading lower. The company reported Q2 financial results.

Guidance

As Of June 30, 2024, BioLineRx Had Cash, Cash Equivalents, And Short-term Bank Deposits Of $40.1M Expected To Be Sufficient To Fund Operations, As Currently Planned, Into 2025

BioLine Rx Q2 2024 GAAP EPS $0.00 Beats $(0.14) Estimate, Sales $5.393M Beat $3.930M Estimate

BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

BioLineRx shares are trading higher. The company reported Q1 financial results.

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BiolineRx Ltd., an Israeli company, has announced a registered direct offering involvin...

BiolineRx Ltd. Announces New Direct Offering of Shares

BioLineRx inks licensing deal, share purchase agreement

BioLineRx Q3 2024 Earnings Preview

BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has entered a strategic license agreement with Ayrmid Ltd. for its APHEXD...

BioLineRx Secures Key Deals to Boost Shareholder Value

Reports Q3 revenue $4.94M. No revenue reported in Q3 of last year. "The license agreement for APHEXDA that we announced last week was made possible...

BioLineRx reports Q3 EPS 0c vs. (2c) last year

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

H.C. Wainwright lowered the firm's price target on BioLineRx (BLRX) to $9 from $21 and keeps a Buy rating on the shares after the company announced...

BioLineRx price target lowered to $9 from $21 at H.C. Wainwright

Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has released its Q3 earnings. Here is a breakdown of the information Bioline RX Ltd Sponsored ADR presente...

BioLineRx Reports Strategic Moves in Q3 2024

JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR (BLRX – Research Report) today. The company's shares open...

JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)

GMDAQ

Small Cap

Press Releases

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Management

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Comments

BioLine Rx

Noticias

Últimas noticias sobre BioLine Rx (NASDAQ:BLRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL